Calithera Biosciences Stock Price, News & Analysis

Calithera Biosciences Inc. (CALA) is a pioneering biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule drugs aimed at slowing tumor growth. Their approach focuses on controlling key metabolic pathways in both tumor and immune cells, targeting the distinct metabolic requirements of these cells to impede cancer proliferation.

Calithera leverages the promising fields of tumor metabolism and tumor immunology to create new, innovative cancer therapies. Recent clinical successes highlight the potential of their investigational medicines to slow abnormal cell growth and offer fundamentally new treatment options for cancer patients.

Currently, Calithera's lead candidate is in Phase 2 trials for patients with renal cell carcinoma and triple negative breast cancer. These trials are crucial given the urgent need for new treatments in these solid tumors.

Calithera also engages in strategic partnerships to bolster its research and development efforts. Their onco-metabolism approach aims to bring a fresh perspective to cancer treatment by exploiting the unique metabolic needs of cancer cells versus cancer-fighting immune cells.

For more information, latest updates, and significant news regarding Calithera Biosciences Inc., visit their official webpage or contact them directly.